Antimicrobial Resistance (AMR) is an alarming global health crisis, with the World Health Organization predicting it could become the leading cause of death by 2050, surpassing cancer and heart disease. A key contributor to this crisis is the challenge of timely and accurate diagnosis, particularly for common infections like Urinary Tract Infections (UTIs), which affect millions worldwide each year, especially women. Delayed diagnosis of UTIs not only causes prolonged discomfort and increased risk of complications but also results in the overuse of broad-spectrum antibiotics, which exacerbates AMR. Without rapid, precise diagnostics, healthcare providers often resort to empirical treatments, fueling resistance and allowing resistant pathogens to spread. Urgent action is needed to develop diagnostics that can identify pathogens and their antibiotic susceptibility in real-time, providing targeted treatments to combat both UTI-related complications and the global AMR pandemic.

Rapiddx Technologies has developed the r-PASA (Rapid Personalized Antibiotic Susceptibility Assay), an automated, accurate test for detecting antibiotic susceptibility in urinary tract infections (UTIs) and ESKAPE pathogens. Utilizing advanced diagnostic technology, r-PASA delivers results from urine samples within 5-6 hours, providing essential information on antibiotic effectiveness. This rapid testing helps doctors make timely treatment decisions, addressing both UTI infections and resistant bacteria. Validated against Clinical and Laboratory Standards Institute standards, r-PASA ensures reliability with its automated, multiplexed analysis. By improving diagnostic speed and accuracy, r-PASA is set to enhance healthcare in tier II and III cities, reduce antibiotic overuse, and improve health outcomes for underserved populations in India.